Page 1 | Search Results | Journal of Experimental Medicine

Skip Nav Destination

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes.

S L Topalian, M I Gonzales, M Parkhurst, Y F Li, S Southwood, A Sette, S A Rosenberg, P F Robbins

J Exp Med (1996) 183 (5): 1965–1971.

https://doi.org/10.1084/jem.183.5.1965

Published: 01 May 1996

View article titled, Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes.

Journal Articles

A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes.

P F Robbins, M El-Gamil, Y F Li, Y Kawakami, D Loftus, E Appella, S A Rosenberg

J Exp Med (1996) 183 (3): 1185–1192.

https://doi.org/10.1084/jem.183.3.1185

Published: 01 March 1996

View article titled, A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes.

Journal Articles

Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen.

R F Wang, M R Parkhurst, Y Kawakami, P F Robbins, S A Rosenberg

J Exp Med (1996) 183 (3): 1131–1140.

https://doi.org/10.1084/jem.183.3.1131

Published: 01 March 1996

View article titled, Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen.

Journal Articles

Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes.

R F Wang, P F Robbins, Y Kawakami, X Q Kang, S A Rosenberg

J Exp Med (1995) 181 (2): 799–804.

https://doi.org/10.1084/jem.181.2.799

Published: 01 February 1995

View article titled, Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes.

Journal Articles

Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes.

Y Kawakami, S Eliyahu, K Sakaguchi, P F Robbins, L Rivoltini, J R Yannelli, E Appella, S A Rosenberg

J Exp Med (1994) 180 (1): 347–352.

https://doi.org/10.1084/jem.180.1.347

Published: 01 July 1994

View article titled, Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes.

Journal Articles

Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes.

A B Bakker, M W Schreurs, A J de Boer, Y Kawakami, S A Rosenberg, G J Adema, C G Figdor

J Exp Med (1994) 179 (3): 1005–1009.

https://doi.org/10.1084/jem.179.3.1005

Published: 01 March 1994

View article titled, Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes.

Journal Articles

Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain.

P Hwu, G E Shafer, J Treisman, D G Schindler, G Gross, R Cowherd, S A Rosenberg, Z Eshhar

J Exp Med (1993) 178 (1): 361–366.

https://doi.org/10.1084/jem.178.1.361

Published: 01 July 1993

View article titled, Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain.

Journal Articles

Identification of human cancers deficient in antigen processing.

N P Restifo, F Esquivel, Y Kawakami, J W Yewdell, J J Mulé, S A Rosenberg, J R Bennink

J Exp Med (1993) 177 (2): 265–272.

https://doi.org/10.1084/jem.177.2.265

Published: 01 February 1993

View article titled, Identification of human cancers deficient in antigen processing.

Journal Articles

A nonimmunogenic sarcoma transduced with the cDNA for interferon gamma elicits CD8+ T cells against the wild-type tumor: correlation with antigen presentation capability.

N P Restifo, P J Spiess, S E Karp, J J Mulé, S A Rosenberg

J Exp Med (1992) 175 (6): 1423–1431.

https://doi.org/10.1084/jem.175.6.1423

Published: 01 June 1992

View article titled, A nonimmunogenic sarcoma transduced with the cDNA for interferon gamma elicits CD8+ T cells against the wild-type tumor: correlation with antigen presentation capability.

Journal Articles

Interleukin 7 generates antitumor cytotoxic T lymphocytes against murine sarcomas with efficacy in cellular adoptive immunotherapy.

D L Jicha, J J Mulé, S A Rosenberg

J Exp Med (1991) 174 (6): 1511–1515.

https://doi.org/10.1084/jem.174.6.1511

Published: 01 December 1991

View article titled, Interleukin 7 generates antitumor cytotoxic T lymphocytes against murine sarcomas with efficacy in cellular adoptive immunotherapy.

Journal Articles

Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes.

R J Barth, Jr, J J Mulé, P J Spiess, S A Rosenberg

J Exp Med (1991) 173 (3): 647–658.

https://doi.org/10.1084/jem.173.3.647

Published: 01 March 1991

View article titled, Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes.

Journal Articles

Antitumor activity of recombinant interleukin 6 in mice.

J J Mulé, J K McIntosh, D M Jablons, S A Rosenberg

J Exp Med (1990) 171 (3): 629–636.

https://doi.org/10.1084/jem.171.3.629

Published: 01 March 1990

View article titled, Antitumor activity of recombinant interleukin 6 in mice.

Journal Articles

Synergistic antitumor activity of tumor-infiltrating lymphocytes, interleukin 2, and local tumor irradiation. Studies on the mechanism of action.

R B Cameron, P J Spiess, S A Rosenberg

J Exp Med (1990) 171 (1): 249–263.

https://doi.org/10.1084/jem.171.1.249

Published: 01 January 1990

View article titled, Synergistic antitumor activity of tumor-infiltrating lymphocytes, interleukin 2, and local tumor irradiation. Studies on the mechanism of action.

Journal Articles

Interleukin 4 promotes the growth of tumor-infiltrating lymphocytes cytotoxic for human autologous melanoma.

Y Kawakami, S A Rosenberg, M T Lotze

J Exp Med (1988) 168 (6): 2183–2191.

https://doi.org/10.1084/jem.168.6.2183

Published: 01 December 1988

View article titled, Interleukin 4 promotes the growth of tumor-infiltrating lymphocytes cytotoxic for human autologous melanoma.

Journal Articles

Immunotherapy of a murine tumor with interleukin 2. Increased sensitivity after MHC class I gene transfection.

J S Weber, G Jay, K Tanaka, S A Rosenberg

J Exp Med (1987) 166 (6): 1716–1733.

https://doi.org/10.1084/jem.166.6.1716

Published: 01 December 1987

View article titled, Immunotherapy of a murine tumor with interleukin 2. Increased sensitivity after MHC class I gene transfection.

Journal Articles

Interleukin 4 (B cell stimulatory factor 1) can mediate the induction of lymphokine-activated killer cell activity directed against fresh tumor cells.

J J Mulé, C A Smith, S A Rosenberg

J Exp Med (1987) 166 (3): 792–797.

https://doi.org/10.1084/jem.166.3.792

Published: 01 September 1987

View article titled, Interleukin 4 (B cell stimulatory factor 1) can mediate the induction of lymphokine-activated killer cell activity directed against fresh tumor cells.

Journal Articles

Immunization with antigen and interleukin 2 in vivo overcomes Ir gene low responsiveness.

H Kawamura, S A Rosenberg, J A Berzofsky

J Exp Med (1985) 162 (1): 381–386.

https://doi.org/10.1084/jem.162.1.381

Published: 01 July 1985

View article titled, Immunization with antigen and interleukin 2 in vivo overcomes Ir gene low responsiveness.

Journal Articles

Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.

S A Rosenberg, J J Mulé, P J Spiess, C M Reichert, S L Schwarz

J Exp Med (1985) 161 (5): 1169–1188.

https://doi.org/10.1084/jem.161.5.1169

Published: 01 May 1985

View article titled, Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.

Journal Articles

Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2.

A Mazumder, S A Rosenberg

J Exp Med (1984) 159 (2): 495–507.

https://doi.org/10.1084/jem.159.2.495

Published: 01 February 1984

View article titled, Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2.

Journal Articles

Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells.

E A Grimm, R J Robb, J A Roth, L M Neckers, L B Lachman, D J Wilson, S A Rosenberg

J Exp Med (1983) 158 (4): 1356–1361.

https://doi.org/10.1084/jem.158.4.1356

Published: 01 October 1983

View article titled, Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells.

NARROW

Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes.

A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes.

Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen.

Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes.

Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes.

Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes.

Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain.

Identification of human cancers deficient in antigen processing.

A nonimmunogenic sarcoma transduced with the cDNA for interferon gamma elicits CD8+ T cells against the wild-type tumor: correlation with antigen presentation capability.

Interleukin 7 generates antitumor cytotoxic T lymphocytes against murine sarcomas with efficacy in cellular adoptive immunotherapy.

Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes.

Antitumor activity of recombinant interleukin 6 in mice.

Synergistic antitumor activity of tumor-infiltrating lymphocytes, interleukin 2, and local tumor irradiation. Studies on the mechanism of action.

Interleukin 4 promotes the growth of tumor-infiltrating lymphocytes cytotoxic for human autologous melanoma.

Immunotherapy of a murine tumor with interleukin 2. Increased sensitivity after MHC class I gene transfection.

Interleukin 4 (B cell stimulatory factor 1) can mediate the induction of lymphokine-activated killer cell activity directed against fresh tumor cells.

Immunization with antigen and interleukin 2 in vivo overcomes Ir gene low responsiveness.

Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.

Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2.

Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells.

Email alerts

Email alerts

This Feature Is Available To Subscribers Only